ArticleBreast cancer research : BCR2020

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancer.

Samuel A Jacobs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.